BASTIDE LE CONFORT MEDICAL (BLC.PA) Fundamental Analysis & Valuation

EPA:BLC • FR0000035370

23.85 EUR
0 (0%)
Last: Mar 12, 2026, 10:14 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This BLC.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Overall BLC gets a fundamental rating of 4 out of 10. We evaluated BLC against 33 industry peers in the Health Care Providers & Services industry. BLC has a medium profitability rating, but doesn't score so well on its financial health evaluation. BLC has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

5

1. BLC.PA Profitability Analysis

1.1 Basic Checks

  • In the past year BLC was profitable.
  • In the past year BLC had a positive cash flow from operations.
  • BLC had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years BLC had a positive operating cash flow.
BLC.PA Yearly Net Income VS EBIT VS OCF VS FCFBLC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M 100M

1.2 Ratios

  • The Return On Assets of BLC (0.08%) is worse than 72.73% of its industry peers.
  • With a Return On Equity value of 0.74%, BLC is not doing good in the industry: 72.73% of the companies in the same industry are doing better.
  • The Return On Invested Capital of BLC (6.43%) is better than 69.70% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BLC is in line with the industry average of 6.06%.
  • The last Return On Invested Capital (6.43%) for BLC is above the 3 year average (6.14%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.08%
ROE 0.74%
ROIC 6.43%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
BLC.PA Yearly ROA, ROE, ROICBLC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • BLC has a worse Profit Margin (0.11%) than 72.73% of its industry peers.
  • In the last couple of years the Profit Margin of BLC has declined.
  • BLC has a Operating Margin of 8.21%. This is in the better half of the industry: BLC outperforms 63.64% of its industry peers.
  • BLC's Operating Margin has been stable in the last couple of years.
  • The Gross Margin of BLC (67.80%) is better than 75.76% of its industry peers.
  • In the last couple of years the Gross Margin of BLC has grown nicely.
Industry RankSector Rank
OM 8.21%
PM (TTM) 0.11%
GM 67.8%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
BLC.PA Yearly Profit, Operating, Gross MarginsBLC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BLC.PA Health Analysis

2.1 Basic Checks

  • BLC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, BLC has about the same amount of shares outstanding.
  • The number of shares outstanding for BLC remains at a similar level compared to 5 years ago.
  • The debt/assets ratio for BLC has been reduced compared to a year ago.
BLC.PA Yearly Shares OutstandingBLC.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
BLC.PA Yearly Total Debt VS Total AssetsBLC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • BLC has an Altman-Z score of 1.39. This is a bad value and indicates that BLC is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of BLC (1.39) is worse than 60.61% of its industry peers.
  • The Debt to FCF ratio of BLC is 12.90, which is on the high side as it means it would take BLC, 12.90 years of fcf income to pay off all of its debts.
  • BLC has a worse Debt to FCF ratio (12.90) than 60.61% of its industry peers.
  • BLC has a Debt/Equity ratio of 5.29. This is a high value indicating a heavy dependency on external financing.
  • BLC's Debt to Equity ratio of 5.29 is on the low side compared to the rest of the industry. BLC is outperformed by 87.88% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.29
Debt/FCF 12.9
Altman-Z 1.39
ROIC/WACC1.28
WACC5.02%
BLC.PA Yearly LT Debt VS Equity VS FCFBLC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 1.38 indicates that BLC should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.38, BLC is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
  • BLC has a Quick Ratio of 1.18. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
  • BLC has a Quick ratio of 1.18. This is in the better half of the industry: BLC outperforms 75.76% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.18
BLC.PA Yearly Current Assets VS Current LiabilitesBLC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. BLC.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 158.33% over the past year.
  • Measured over the past years, BLC shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -46.37% on average per year.
  • BLC shows a small growth in Revenue. In the last year, the Revenue has grown by 6.35%.
  • BLC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.12% yearly.
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%

3.2 Future

  • BLC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.90% yearly.
  • BLC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.69% yearly.
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BLC.PA Yearly Revenue VS EstimatesBLC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BLC.PA Yearly EPS VS EstimatesBLC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

4

4. BLC.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 340.71, the valuation of BLC can be described as expensive.
  • 75.76% of the companies in the same industry are cheaper than BLC, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of BLC to the average of the S&P500 Index (26.15), we can say BLC is valued expensively.
  • A Price/Forward Earnings ratio of 12.93 indicates a correct valuation of BLC.
  • 69.70% of the companies in the same industry are more expensive than BLC, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 24.27. BLC is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 340.71
Fwd PE 12.93
BLC.PA Price Earnings VS Forward Price EarningsBLC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BLC is valued cheaper than 90.91% of the companies in the same industry.
  • 81.82% of the companies in the same industry are more expensive than BLC, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 5.51
EV/EBITDA 5.56
BLC.PA Per share dataBLC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.23%
EPS Next 3Y5.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BLC.PA Dividend Analysis

5.1 Amount

  • BLC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BLC.PA Fundamentals: All Metrics, Ratios and Statistics

BASTIDE LE CONFORT MEDICAL

EPA:BLC (3/12/2026, 10:14:29 AM)

23.85

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-13
Earnings (Next)03-18
Inst Owners12.76%
Inst Owner ChangeN/A
Ins Owners1.63%
Ins Owner ChangeN/A
Market Cap175.77M
Revenue(TTM)491.18M
Net Income(TTM)533.00K
Analysts77.14
Price Target36.21 (51.82%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP106.75%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.39%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-8.26%
EPS NY rev (3m)-26.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.26%
Revenue NY rev (3m)0.26%
Valuation
Industry RankSector Rank
PE 340.71
Fwd PE 12.93
P/S 0.36
P/FCF 5.51
P/OCF 1.91
P/B 2.44
P/tB N/A
EV/EBITDA 5.56
EPS(TTM)0.07
EY0.29%
EPS(NY)1.84
Fwd EY7.73%
FCF(TTM)4.32
FCFY18.13%
OCF(TTM)12.48
OCFY52.31%
SpS66.65
BVpS9.79
TBVpS-16.26
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.93
Profitability
Industry RankSector Rank
ROA 0.08%
ROE 0.74%
ROCE 8.75%
ROIC 6.43%
ROICexc 6.81%
ROICexgc 12.17%
OM 8.21%
PM (TTM) 0.11%
GM 67.8%
FCFM 6.49%
ROA(3y)0.59%
ROA(5y)1.26%
ROE(3y)4.45%
ROE(5y)9.21%
ROIC(3y)6.14%
ROIC(5y)5.72%
ROICexc(3y)6.57%
ROICexc(5y)6.12%
ROICexgc(3y)13.99%
ROICexgc(5y)12.76%
ROCE(3y)8.36%
ROCE(5y)7.81%
ROICexgc growth 3Y3.04%
ROICexgc growth 5Y-0.89%
ROICexc growth 3Y7.75%
ROICexc growth 5Y0.36%
OM growth 3Y5.49%
OM growth 5Y0.75%
PM growth 3Y-66.74%
PM growth 5Y-48.72%
GM growth 3Y1.15%
GM growth 5Y6.69%
F-Score8
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 5.29
Debt/FCF 12.9
Debt/EBITDA 3.78
Cap/Depr 99.07%
Cap/Sales 12.23%
Interest Coverage 250
Cash Conversion 91.09%
Profit Quality 5980.3%
Current Ratio 1.38
Quick Ratio 1.18
Altman-Z 1.39
F-Score8
WACC5.02%
ROIC/WACC1.28
Cap/Depr(3y)93.32%
Cap/Depr(5y)92.23%
Cap/Sales(3y)11.17%
Cap/Sales(5y)11.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)158.33%
EPS 3Y-66.43%
EPS 5Y-46.37%
EPS Q2Q%-107.14%
EPS Next Y-12.23%
EPS Next 2Y-1.23%
EPS Next 3Y5.9%
EPS Next 5YN/A
Revenue 1Y (TTM)6.35%
Revenue growth 3Y1.6%
Revenue growth 5Y5.12%
Sales Q2Q%9.55%
Revenue Next Year4.14%
Revenue Next 2Y4.76%
Revenue Next 3Y5.03%
Revenue Next 5Y7.69%
EBIT growth 1Y18.78%
EBIT growth 3Y7.18%
EBIT growth 5Y5.9%
EBIT Next Year138.04%
EBIT Next 3Y38.82%
EBIT Next 5YN/A
FCF growth 1Y1.48%
FCF growth 3Y107.15%
FCF growth 5Y33.43%
OCF growth 1Y13.72%
OCF growth 3Y17.38%
OCF growth 5Y14.21%

BASTIDE LE CONFORT MEDICAL / BLC.PA FAQ

Can you provide the ChartMill fundamental rating for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a fundamental rating of 4 / 10 to BLC.PA.


Can you provide the valuation status for BASTIDE LE CONFORT MEDICAL?

ChartMill assigns a valuation rating of 4 / 10 to BASTIDE LE CONFORT MEDICAL (BLC.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for BASTIDE LE CONFORT MEDICAL?

BASTIDE LE CONFORT MEDICAL (BLC.PA) has a profitability rating of 5 / 10.


What is the expected EPS growth for BASTIDE LE CONFORT MEDICAL (BLC.PA) stock?

The Earnings per Share (EPS) of BASTIDE LE CONFORT MEDICAL (BLC.PA) is expected to decline by -12.23% in the next year.


Can you provide the dividend sustainability for BLC stock?

The dividend rating of BASTIDE LE CONFORT MEDICAL (BLC.PA) is 0 / 10 and the dividend payout ratio is 106.75%.